Patients want to stay alive but also value maintaining QoL[2][3]
ERLEADA® + ADT significantly improved OS vs. placebo + ADT while maintaining HRQoL.[1]a
HRQoL was maintained from baseline after the addition of ERLEADA® to ADT treatment[1]
Change in FACT-P PWB subscale score from baseline[1]
Adapted from Chi KN, et al. 2021.
aIn the TITAN final analysis, patient-reported outcomes for HRQoL were assessed by means of the FACT-P questionnaire. A change of 6 to 10 points in the FACT-P total score is the minimally important difference.[1]
bIn the Agarwal analysis from 2019, the median follow-up for time to pain-related endpoints ranged from 19.4 to 22.1 months.[4]
Treat early with ERLEADA® + ADT to delay progression and extend life for your mHSPC patients vs. placebo + ADT[1]
Extend life across a broad range of mHSPC patients with ERLEADA® + ADT[1]
Extend life and push back on progression in mHSPC with a consistent safety profile[1]
Abbreviations
ADT, androgen deprivation therapy. FACT-P, Functional Assessment of Cancer Therapy – Prostate. HRQoL, health-related quality of life. mHSPC, metastatic hormone-sensitive prostate cancer. OS, overall survival. PWB, psychological well-being. QoL, quality of life.
Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.
Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.
Antes de prescrever consulte o RCM completo.
RCM de Erleada®, veja aqui
